Key result
Functional assays significantly misestimate DOAC levels in lupus anticoagulant-positive patients compared to LC-MS.
Why the study?
DOAC effects on factor IIa- and Xa-dependent laboratory tests can cause false results, presenting a complex challenge in patients who develop lupus anticoagulant antibodies.
Does the presence of lupus anticoagulant interfere with the determination of DOAC levels by functional assays compared to LC-MS?
Observational (n=31)
Does the presence of lupus anticoagulant interfere with the determination of DOAC levels by functional assays compared to LC-MS?
In patients with lupus anticoagulant, functional assays are unreliable for measuring DOAC levels, and LC-MS should be used instead.
Answers are grounded in this paper and cite their sources.
May warrant LC-MS confirmation of DOAC levels in lupus anticoagulant-positive patients; leaves open whether this improves outcomes.
BACKGROUND: The effect of direct oral anticoagulants (DOAC) on laboratory tests dependent on the production of their targets, factor IIa and factor Xa, is a well-known problem and can cause both false positive and negative results. In particular, the situation in patients who develop lupus anticoagulant (LA) antibodies is highly complex. To evaluate the effectiveness of DOAC therapy in lupus-positive patients, 31 samples were enrolled in this retrospective study. All patient samples were spiked with three types of DOAC (dabigatran, DABI; rivaroxaban, RIVA; and apixaban, API) in a concentration that significantly influenced the screening test for LA and thus can mask the presence of LA. Subsequently, the DOAC was always unbound by the DOAC-Stop procedure. DOAC levels before and after binding were determined by functional assays, followed by liquid chromatography coupled with mass spectrometry (LC-MS) analysis. METHODS: The determination of DOAC levels was performed by direct thrombin assay and determination of anti-Xa activity with specific calibration as functional tests for DABI and xabans (API and RIVA). To determine concentration levels of API, DABI, and RIVA, our in-house LC-MS method was used. RESULTS: The results of LA-positive samples show significant differences between functional tests and the LC-MS method both before and after DOAC binding. CONCLUSIONS: The acute findings of the presence of LA-type antibodies fundamentally affects the determination of DOAC by functional tests, and in this case, it is necessary to use LC-MS analysis to determine the true value. If patients treated with DOAC develop LA of medium and higher titers, we do not recommend checking DOAC levels with functional tests.
No takes yet. Share an insight, caveat, or question.
Úlehlová et al. (2021) conducted an observational in Lupus anticoagulant (LA) positive (n=31). Functional assays (dTT, anti-Xa) vs. LC-MS was evaluated on DOAC concentration levels (p=<0.05). In lupus anticoagulant-positive samples, functional tests misestimated DOAC levels compared to LC-MS, indicating LC-MS is necessary for accurate measurement.
Synapse has enriched 10 related papers. Consider them for comparative context: